s and Presentations" section. There will be a slide presentation to accompany the call, which will also be available on this section of the Dendreon website. A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-888-203-1112 (domestic) or 719-457-0820 (international); the conference ID number is 6483399. The replay will be available from 8:00 p.m. ET, April 28, 2009 until midnight April 29, 2009. In addition, the webcast will be archived for on-demand listening for 30 days at
www.dendreon.com.
About Dendreon
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com.
'/>"/>SOURCE Dendreon Corporation Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 Related biology technology :1.
Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer2.
Dendreon Reports Fourth Quarter and 2008 Year End Financial Results3.
Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference4.
Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference5.
Dendreon Reports Third Quarter 2008 Financial Results6.
Dendreon Announces Webcast Presentations at Upcoming Investor Conferences7.
Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist8.
Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference9.
Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference10.
Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer11.
Dendreon Reports First Quarter 2008 Financial Results